Inventaire - your friends and communities are your best library

Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.

author

Brian Ruffell

Tomasz M Beer

Celestia Higano

published in: Anti-Cancer Drugs

date of publication: 2017-01-01

main subject: docetaxel

Cites articles 29

Date

Title

Authors

2015

Cancer statistics, 2015
2015-08-05

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015-05-28

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Alain Ravaud, Jean-Luc Labourey, Philippe Beuzeboc, Nadine Houédé
2015-02-07

Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy
2014-05-20

High-risk prostate cancer-classification and therapy

Mack Roach
2013-12-12

The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton
2012-02-01

PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer
2011-08-08

Leukocyte composition of human breast cancer

Brian Ruffell, Laura Esserman, Hope Rugo
2010-01-01

Treatment strategies for high-risk locally advanced prostate cancer
2010-02-01

Time trends and local variation in primary treatment of localized prostate cancer

Matthew R Cooperberg
2010-04-01

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer

Catherine A O'Brien, Tomasz M Beer, Celestia Higano
2008-04-01

Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells

Lionel Apetoh, Bruno Coudert, Francois Ghiringhelli, François Martin
2007-06-01

Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure

Yan Yan, Adam S Kibel
2007-02-01

Prostate specific antigen density correlates with features of prostate cancer aggressiveness
2007-06-01

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

Alan W Partin, Patrick Craig Walsh, Bruce J Trock, Danil V Makarov, Leslie Mangold, Jonathan I Epstein
2006-05-01

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy
2005-04-01

Rising prostate-specific antigen after primary prostate cancer therapy
2005-11-01

Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy
2004-02-01

Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer

Tomasz M Beer, Celestia Higano
2004-05-01

Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations

Alan W Partin
2004-08-01

The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer
2003-11-01

Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.

Michael J Zelefsky, Deborah Kuban, Lawrence B Levy, Patrick A. Kupelian, Eric M Horwitz, Jeff Michalski, Thomas M Pisansky, Howard Sandler, Bill Shipley, Anthony L Zietman, Howard D. Thames
2002-10-01

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial
2002-09-01

Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience

Laurence Klotz
2002-01-01

Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results
2001-08-01

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience
2001-08-01

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects
1999-01-01

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer
1999-09-01

High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group.

Jean-Michel Goujon

Article - wd:Q50486621

Welcome to Inventaire

the library of your friends and communities

learn more